<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414933</url>
  </required_header>
  <id_info>
    <org_study_id>GRT01/0710 SAFIR-01</org_study_id>
    <nct_id>NCT01414933</nct_id>
  </id_info>
  <brief_title>High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents</brief_title>
  <acronym>SAFIR-01</acronym>
  <official_title>High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High sensitivity to targeted agents has been observed in patients whose tumor cells present a
      genetic/genomic deregulation of the target (Kit mutation, ERBB2 amplification, EGFR
      mutations) together with addiction to the given target. More recently, activation of
      &quot;alternative pathways&quot; (Kras mutation, PI3K mutations) have been reported as a common
      resistance mechanism to single agent tyrosine kinase inhibitors (trastuzumab, cetuximab).

      From these data has emerged the hypothesis that identification of the deregulated pathway
      through new molecular tools could allow to propose a more tailored targeted regimen.

      Based on these concepts, numbers of phase I/II trials enrich their populations in patients
      presenting specific molecular alterations.

      High throughput technologies (array CGH, sequencing, gene expression array) identify
      deregulated genes. In addition, these technologies determine whether such genomic alterations
      are single (expected efficacy of single agent) or multiple (rationale for combination). In a
      pilot study that included 135 patients, we recently performed a combination of array CGH and
      hot spot mutation array in order to drive patients into phase I/II clinical trials. This
      study led to the conclusions that high throughput technologies i. are feasible (80%) and
      robust, ii. identify &quot;targetable&quot; genomic alterations in around 40% of samples.

      In the present study, the investigators will perform high throughput technologies to drive
      400 metastatic breast cancer patients into specific phase I/II trials.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients included in early phase trials evaluating targeted drugs</measure>
    <time_frame>one year after obtaining the molecular profile</time_frame>
    <description>To use whole genome / integrated biology approach to drive patients in early clinical trials. The goal is to include at least 30% of the patients in a clinical trial evaluating targeted agent, according to the molecular alteration detected on high throughput technologies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years after inclusion in SAFIR</time_frame>
    <description>To evaluate the efficacy of such patient selection in terms of survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years after inclusion in SAFIR</time_frame>
    <description>To evaluate the efficacy of such patient selection in terms of progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of such patient selection in terms of survival response rate</measure>
    <time_frame>3 years after inclusion in SAFIR</time_frame>
    <description>To evaluate the efficacy of such patient selection in terms of best response rate</description>
  </secondary_outcome>
  <enrollment type="Actual">423</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Breast metastases biopsy</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Metastasis biopsy and DNA from biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        women or men with metastatic breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Women with histologically diagnosed breast cancer

          -  Metastatic relapse or stage IV breast cancer at diagnosis

          -  Metastases amenable to biopsy

          -  Age &lt;70 years old

          -  PS 0/1

          -  No restriction regarding the number of previous chemotherapy or endocrine therapies

        Exclusion Criteria:

          -  Age &lt;18

          -  Life expectancy &lt;3 months

          -  Symptomatic or progressing brain metastases

          -  Progressive patients at the time of biopsy

          -  LVEF &lt;50% (MUGA or ultrasonography)

          -  Inadequate bone marrow reserve or organ function as demonstrated by any of the
             following laboratory values:

               -  Absolute neutrophil count &lt; 1.5 x 109/L

               -  Platelet count &lt; 100 x 109/L

               -  Haemoglobin &lt; 90 g/L

               -  ASAT/ALAT &gt; 2.5 times the upper limit of normal (ULN) if no demonstrable liver
                  metastases or &gt; 5 times ULN in the presence of liver metastases

               -  Total bilirubin &gt; 1.5 times ULN

               -  Creatinine &gt;1.5 times ULN

               -  Corrected calcium &gt; ULN

               -  Phosphate &gt; ULN

          -  Abnormal blood coagulation that contra-indicates biopsy

          -  Patients deprived of liberty or placed under the authority of a tutor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice André, MD phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, Villejuif, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest/ René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie/ René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol. 2011 Apr 1;29(10):1236-8. doi: 10.1200/JCO.2010.31.6877. Epub 2011 Feb 22.</citation>
    <PMID>21343554</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

